MarketCapExport financials
Profound Medical Corp. (PROF)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Profound Medical Corp. Income Statement 2025-2011 | PROF
Brief overview of profit and loss at Profound Medical Corp.
The comparison covers a five-year financial horizon. Revenue reported by Profound Medical Corp. was 7.3 million dollars at the beginning of the period and 16.1 million dollars at the end. The total change was +120.4%, with a CAGR of approximately 17.1%. Revenue followed a strong upward trend without signs of stagnation.
Gross profit changed from 3.5 million dollars to 11.4 million dollars (+228%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 47.6% to 70.8%. Improving gross profitability strengthens the quality of revenue growth.
The five-year EBITDA result moved by −116.7%: from −$18.9 million to −$40.9 million. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −258.3% to −254%. The increased EBITDA share is a positive sign.
The net financial result changed from −$21.6 million to −$42.6 million. The period ended with a larger loss than it began with.
Over the period, capitalization shifted from 228 million dollars to 166 million dollars (−27.2%). Capitalization lags the underlying business improvement.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The positive side is supported by revenue expansion, a stronger gross margin and positive operating leverage. Caution is warranted because of declining net profitability, a weaker market valuation and a low EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Profound Medical Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
166 M | 185 M | 173 M | 183 M | 230 M | 228 M | 121 M | 88.1 M | - | - | - | - | - | - | - |
Shares |
30.2 M | 24.8 M | 21.2 M | 20.8 M | 20.5 M | 11.1 M | 11.1 M | 10 M | - | - | - | - | - | - | - |
Historical Prices |
5.49 | 7.45 | 8.18 | 8.78 | 11.2 | 20.6 | 10.9 | - | - | - | - | - | - | - | - |
Net Income |
-42.6 M | -27.8 M | -28.3 M | -28.7 M | -30.7 M | -21.6 M | -20.2 M | -20.8 M | -18.8 M | -12.1 M | -11.8 M | -8.2 M | - | - | - |
Revenue |
16.1 M | 10.7 M | 7.2 M | 6.68 M | 6.87 M | 7.3 M | 4.17 M | 2.6 M | 4.9 M | - | - | - | - | - | - |
Cost of Revenue |
4.7 M | 3.64 M | 2.89 M | 3.66 M | 3.92 M | 3.83 M | 1.78 M | - | - | - | - | - | - | - | - |
Gross Profit |
11.4 M | 7.04 M | 4.31 M | 3.02 M | 2.95 M | 3.47 M | - | - | 1.87 M | - | - | - | - | - | - |
Operating Income |
-41.3 M | -33.1 M | -28.7 M | -32.1 M | -30.3 M | -18.9 M | -14.9 M | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | 146 K | 290 K | 448 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-40.9 M | -32.4 M | -27.9 M | -32.1 M | -30.3 M | -18.9 M | -14.9 M | - | -17.2 M | -11.4 M | -9.39 M | -6.18 M | - | - | - |
Operating Expenses |
52.6 M | 40.1 M | 33 M | 35.1 M | 33.2 M | 22.3 M | 17.3 M | 21 M | 19.5 M | - | - | - | - | - | - |
General and Administrative Expenses |
32.1 M | 23.1 M | 9.17 M | 9.46 M | 10.3 M | 7.56 M | 7.68 M | 6.66 M | 5.94 M | 4.2 M | 4.39 M | 1.95 M | - | - | - |
All numbers in USD currency
Quarterly Income Statement Profound Medical Corp.
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
36.4 M | 36.3 M | 30.1 M | 30.1 M | 30 M | 21.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.54 M | -7.05 M | -7.98 M | -15.7 M | -10.7 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
2.48 M | 5.34 M | 5.29 M | 2.21 M | 2.62 M | 7.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
536 K | 1.5 M | 1.36 M | 593 K | 768 K | 2.82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.95 M | 3.83 M | 3.93 M | 1.62 M | 1.85 M | 4.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.1 M | -8.02 M | -8.91 M | -13.8 M | -11.2 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | 146 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-10.9 M | -7.93 M | -8.82 M | -13.7 M | -11 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
13 M | 11.9 M | 12.8 M | 15.4 M | 13 M | 33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.36 M | 6.59 M | 7.43 M | 9.33 M | 8.21 M | 9.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Profound Medical Corp. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
IRIDEX Corporation
IRIX
|
$ 0.69 | 7.28 % | $ 11.7 M |  USA |
 |
IRadimed Corporation
IRMD
|
$ 86.47 | 1.25 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.45 | 0.1 % | $ 4.39 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
$ 22.89 | 3.29 % | $ 537 M | USA |
 |
LivaNova PLC
LIVN
|
$ 76.43 | 1.81 % | $ 4.17 B |  Britain |
 |
LENSAR
LNSR
|
$ 6.67 | 0.59 % | $ 79.8 M | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.88 | 2.73 % | $ 76.5 M | USA |
 |
Medtronic PLC
MDT
|
$ 87.97 | 1.88 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.55 | 0.54 % | $ 672 M | USA |
 |
Myomo
MYO
|
$ 1.67 | 2.45 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.64 | 1.15 % | $ 41.5 M |  Israel |
 |
InspireMD
NSPR
|
$ 0.58 | 1.64 % | $ 37.3 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.5 | 4.51 % | $ 376 M |  Curacao |
 |
Outset Medical
OM
|
$ 4.1 | 3.54 % | $ 62.4 K | USA |
 |
PAVmed
PAVM
|
$ 2.66 | 4.36 % | $ 1.78 M | USA |
 |
Penumbra
PEN
|
$ 317.11 | 0.07 % | $ 12.3 B | USA |
 |
Insulet Corporation
PODD
|
$ 135.62 | 2.98 % | $ 9.54 B | USA |
 |
Quanterix Corporation
QTRX
|
$ 3.81 | 4.67 % | $ 162 M | USA |
 |
AVITA Medical
RCEL
|
$ 13.25 | 4.17 % | $ 369 M |  Australia |
 |
Sintx Technologies
SINT
|
$ 2.18 | 1.05 % | $ 6.05 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.92 | 1.87 % | $ 23.3 B | Britain |
 |
Sensus Healthcare
SRTS
|
$ 2.92 | 0.34 % | $ 47.7 M | USA |
 |
Stryker Corporation
SYK
|
$ 285.22 | 3.54 % | $ 109 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.47 | 1.67 % | $ 514 M | USA |
 |
TELA Bio
TELA
|
$ 1.14 | 0.88 % | $ 53.5 M | USA |
 |
TransMedics Group
TMDX
|
$ 82.99 | 4.0 % | $ 2.82 B | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 16.52 | 0.12 % | $ 1.12 B | USA |
 |
Viemed Healthcare
VMD
|
$ 9.24 | 1.2 % | $ 359 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.14 % | $ 764 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.15 | 1.52 % | $ 1.54 M | USA |
 |
Beyond Air
XAIR
|
$ 2.84 | 0.71 % | $ 23.6 B | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.33 | 0.09 % | $ 46 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 91.57 | 3.72 % | $ 18.1 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | Britain |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Invacare Corporation
IVC
|
- | - | $ 24.7 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |